Form 4: BioLife Solutions Executive Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 637 shares of common stock for $23.70 per share to satisfy tax withholding obligations under a pre-existing Rule 10b5-1 trading plan.

Summary

• Aby J. Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported the sale of 637 shares of the company's common stock.
• The transaction occurred on June 10, 2025, with shares sold at a price of $23.70 per share.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted by Mr. Mathew on March 8, 2024.
• The primary purpose of this sale was to cover tax withholding obligations associated with the vesting of restricted stock.
• Following this transaction, Mr. Mathew beneficially owns 353,118 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, pre-planned sale for tax withholding purposes, which is a common occurrence for executives receiving equity compensation and does not indicate a change in company fundamentals or executive confidence.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and routine transaction rather than a discretionary sale based on new information.
• The sale was explicitly for the purpose of satisfying tax withholding obligations, which is a common and expected event for executives receiving equity compensation.

Negatives

• The transaction represents a reduction in direct beneficial ownership by a key executive, though the amount is relatively small and the reason is routine.

Risks

• While the sale was for tax purposes, any insider selling, regardless of reason, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to minor, short-term negative sentiment.

Future Outlook

NA

Industry Context

The sale of shares by executives to cover tax withholding obligations upon the vesting of restricted stock is a standard and common practice across all industries for publicly traded companies. It is a routine part of equity compensation plans and does not typically reflect a change in the company's operational outlook or the executive's long-term confidence.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal as this is a small, routine transaction for tax purposes and does not signal a change in company strategy or performance.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

BioLife Solutions, BLFS, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Tax Withholding, Executive Compensation, Aby J. Mathew